JAN Database Search Results

[Top page]

Search Keyword:Tisotumab Vedotin (Genetical Recombination)
Search Records:1


Tisotumab Vedotin (Genetical Recombination)



Tisotumab Vedotin is an antibody-drug-conjugate (molecular weight: ca. 153,000) consisting of Vedotin ((3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl group (C68H106N11O15; molecular weight: 1,317.63)), which is composed of monomethyl auristatin E and linker, attached to an average of 4 Cys residues of the recombinant monoclonal antibody. The monoclonal antibody moiety is a recombinant human IgG1 monoclonal antibody against human tissue factor and produced in a Chinese hamster ovary cells. The protein moiety is a glycoprotein (molecular weight: ca. 147,500) composed of 2 H-chains (γ1-chains) consisting of 448 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

[1418731-10-8]


Contact Information for Japanese Accepted Names (JAN) Name and Structure Database
jp@nihs.go.jp
National Institute of Health Sciences